dapirolizumab pegol
mAbexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Mar 1, 2010 (NCT01093911)
Timeline
Indications
Mechanism of action
- CD40 ligandINHIBITOR
CD40LG inhibitor
Inhibits, dose-dependently, antigen-specific immune responses to tetanus toxoid in Cynomolgus monkeys.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109478 ↗
Also known as
- cdp7657
- cdp7657
- cdp-7657
- dapirolizumab pegol
- dapirolizumab pegol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06617325 | Phase 3 | Oct 16, 2024 | UCB |
| NCT06555601 | Phase 1 | Jul 31, 2024 | UCB |
| NCT04976322 | Phase 3 | Jul 27, 2021 | UCB |
| NCT04571424 | Phase 1 | Oct 14, 2020 | Anaheim Clinical Trials, Biogen |
| NCT04294667 | Phase 3 | Mar 31, 2020 | UCB |
| NCT02804763 | Phase 2 | Jun 1, 2016 | Hoosier Cancer Research Network |
| NCT01764594 | Phase 1 | Jan 1, 2013 | Biogen, Hoosier Cancer Research Network |
| NCT01093911 | Phase 1 | Mar 1, 2010 | Hoosier Cancer Research Network |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UCB | For profit | 4 | 4 | 2 | 2020 |
| Hoosier Cancer Research Network | Academic/Hospital | 3 | 3 | 2 | 2010 |
| Biogen | For profit | 2 | 1 | 1 | 2013 |
| Anaheim Clinical Trials | For profit | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1